Extra virgin olive oil for liver and metabolic health in MASLD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults aged 18–65 with BMI 20–30 and confirmed hepatic steatosis will be assigned to receive daily extra virgin olive oil supplementation at specified amounts and followed for changes in liver and metabolic outcomes. Steatosis is confirmed by FibroScan CAP (>288 dB/m) or FLI at baseline, and the trial tracks liver fat, blood glucose, lipid profiles, inflammatory markers, body weight and composition during the intervention. The protocol may include gut microbiota analyses to explore mechanisms linking oil intake to metabolic effects. The goal is to determine whether specific supplemental amounts of extra virgin olive oil added to participants' diets produce measurable improvements in liver and cardiometabolic health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects with 20 ≤ BMI \< 30;
* Age range between 18 and 65 years, both sexes;
* Diagnosis of hepatic steatosis, made on the basis of recognized criteria (FibroScan \[CAP (controlled attenuation parameter) \> 288 dB/m\], FLI).

Exclusion Criteria:

* Subjects with BMI \< 20 and BMI \> 30.
* Presence of any condition that may influence the occurrence of steatosis other than the conditions representing inclusion criteria.
* Pregnancy or breastfeeding.
* Severe medical conditions that may compromise participation in the trial.
* Individuals following a special diet.

Where it's running

• UOS Data Science
  Castellana Grotte, Italy, Italy Recruiting

Study contacts

• Study coordinator: Rossella Tatoli, Dietician
• Email: rossella.tatoli@irccsdebellis.it
• Phone: +390804994652

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Concurrent exercise program changes PCSK9 in adults with overweight

  A supervised program of aerobic plus resistance training for eight weeks will test whether it lowers PCSK9 levels in adults who are overweight.

  Recruiting Kastamonu University · Çatalzeytin, Kastamonu · NCT07910916

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.